Case-control studies that analyze the risk factors for antibiotic-resistant organisms have varied epidemiological methodologies, which may lead to biased estimates of antibiotic risk factors. A systematic review of casecontrol studies that analyzed risk factors for antibiotic-resistant organisms addressed 3 methodological principles: method of control group selection, adjustment for time at risk, and adjustment for comorbid illness. A total of 406 abstracts were reviewed. Thirty-seven studies met the inclusion and exclusion criteria and were reviewed and evaluated for the 3 methodological principles. Thirteen (35%) of 37 studies chose the preferred control group. Eleven adjusted for time at risk. Twenty-seven adjusted for comorbid illness. Future studies need to consider more closely the optimization of control group selection, adjusting for confounding caused by time at risk, and adjusting for confounding caused by comorbid illness.
The spread of antibiotic resistance is a major threat to public health. Many investigators have attempted to identify causal risk factors for antibiotic resistance [1, 2] . Potential risk factors that are often of primary interest are individual antibiotics or individual classes of antibiotics. It is hoped that the identification of individual antibiotics as causal parameters and risk factors will lead to interventions or restrictions with regard to antibiotic use that will decrease the emergence of antibiotic resistance.
A variety of study designs may be used to investigate the effects of causal factors, one of which is the casecontrol study. The case-control study is frequently used to identify risk factors for antibiotic-resistant organisms. The importance of certain principles and stan-dards in case-control studies has been outlined repeatedly [3] [4] [5] [6] [7] [8] . However, despite this extensive literature, little has been written with regard to the importance of these case-control methodological standards in studies that analyze antibiotic risk factors for antibiotic-resistant organisms. In addition, methodological issues specific to these antibiotic-resistant studies have not been described.
In this review, we present a systematic review of casecontrol studies that analyzed antibiotic risk factors for antibiotic-resistant organisms, which addresses methodological principles of control group selection and adjustment for confounding factors. We sought to analyze variation in research design across published studies and to evaluate these designs in relation to epidemiological principles and standards.
METHODS
Identification of methodological principles. All authors first reviewed articles and chapters on methodological standards and principles of case-control studies [3] [4] [5] [6] [7] [8] . Important epidemiological principles specific to studies of antibiotic resistance were then discussed. Three specific epidemiological principles for case-control studies were determined to be most important to case-control studies analyzing risk factors for antibiotic resistance. These 3 principles were parallel to key principles discussed by Wacholder et al. [4] and by Rothman and Greenland [5] . Recommendations that addressed these 3 principles were then developed. Identification of studies. After we decided on the 3 methodological issues, we evaluated previous case-control studies with regard to how they addressed these principles and whether they had adhered to the developed recommendations. Studies were identified through a search of MEDLINE for articles published from 1 January 1996 through 1 January 2000 with use of the following search criteria: the subject words "drug resistance," "microbial," and "case-control studies"; the subject words "drug resistance," "microbial," and "risk factors"; the subject words "case control study," combined individually with textwords "vancomycin-resistant enterococci (VRE)," "methicillin-resistant Staphylococcus aureus (MRSA)," and "penicillinresistant Streptococcus pneumoniae"; and the subject words "risk factors," combined individually with textwords "VRE," "MRSA," and "penicillin-resistant S. pneumoniae." One investigator (A.D.H.) reviewed the complete set of titles and abstracts to assess suitability for full review.
Inclusion and exclusion criteria. Inclusion criteria were as follows: use of case-control study design; discussion with regard to individual antibiotics or individual classes of antibiotics, which were evaluated statistically as risk factors; use of human subjects, and presentation in the English language. Studies that were purely descriptive and did not have any statistical test that compared case patients with control patients were excluded. Studies that analyzed risk factors for fungal organisms were excluded.
Assessment of studies. Studies in their entirety were then reviewed independently by 2 investigators (A.D.H. and T.B.K.) to verify that the inclusion and exclusion criteria were met and to assess study design with respect to the 3 principles. For each study, compliance with each developed recommendation was rated according to 4 possible scores: yes, no, uncertain, and not applicable. A third investigator resolved disagreements between the first 2 investigators.
RESULTS
A total of 406 abstracts were reviewed. Forty-nine abstracts met the inclusion and exclusion criteria. Twelve studies were excluded because, on further review, the inclusion criteria were not met. Thirty-seven studies were then reviewed and evaluated for the 3 methodological principles. Among the 37 studies, the outcomes or specific antibiotic-resistant organisms studied were as follows: VRE (11 studies), penicillin-resistant S. pneumoniae (7), antibiotic-resistant Pseudomonas aeruginosa (5), MRSA (3), and other organism (11) . Twenty-six studies (70%) involved of patients who were admitted to acute-care hospitals, 4 (11%) involved long-term care patients, 5 (14%) involved both inpatients and outpatients, and 2 (5%) involved outpatients only. Eleven studies (30%) identified case patients and control patients by means of surveillance cultures; 26 studies (70%) used clinically obtained cultures. Table 1 summarizes the 3 methodological principles and the results of the evaluation of the 37 studies with respect to the developed recommendations. Table 2 lists the individual studies and the characteristics of the studies relative to the 3 methodological principles. A description of the 3 principles and recommendations for addressing these principles are presented below.
Principle 1: method of selection of control groups. The importance of control group selection has been outlined in a number of publications. The identification of the appropriate study base from which to select control patients is the primary challenge in the design of case-control studies. Control patients should be selected from the same source population or study base that gives rise to the case patients. The base should be thought of as the members of the underlying cohort or source population for the case patients during the time periods when they are eligible to become case patients [3] [4] [5] . Estimation of relative risk in a case-control study relies on a comparison of exposure frequency in case patients and control patients. If control patients are selected in a manner such that their frequency of exposure is not representative of the base population, relative risk estimates may be biased [3] [4] [5] 9] .
In studies which analyze antibiotics as individual risk factors for antibiotic-resistant organisms, 2 control groups are chosen most often: patients with cultures that test positive for the Table 2 . Thirty-seven case-control studies which analyzed risk factors for antibiotic resistance that were assessed for adherence to methodological principles.
Study
Organism studied antibiotic-susceptible form of the organism of interest, or a sampling among hospital admissions or office visits or a community of patients at risk for acquisition of the organism. The appropriate choice of control group participants depends on the question being asked. Most hospital-based studies attempt to answer the question, "What are the risk factors for acquiring antibiotic-resistant pathogen X among hospitalized patients?" For this question, patients with culture results that are positive for the antibiotic-susceptible form of the organism of interest do not represent the study base because they are not the source population among which case patients arise. Patients with positive clinical cultures for susceptible organisms generally constitute a relatively small proportion of the total base population.
The choice of patients with susceptible organisms as a control group may lead to biased estimates of relative risk because of a distorted estimate of exposure frequency in the source population. The selection bias introduced by using control patients with susceptible organisms is likely to have the strongest impact on estimating the effect of exposure to antibiotics that are active against susceptible (but not resistant) organisms, which is often the exposure of greatest interest. The reason for this particular bias is that treatment with active antibiotics likely inhibits the growth of susceptible organisms, therefore making this exposure less frequent among patients who are culture-positive for susceptible organisms than among patients in the source population.
The preferred control group for most antibiotic resistance studies that optimally represent the source or base population or underlying cohort is, for studies of hospital-acquired pathogens, the cohort of hospitalized patients, and for communityacquired pathogens, community residents.
One exception is if the specific question is, "What are the risk factors for developing antibiotic-resistant pathogen X among patients with antibiotic-susceptible pathogen X?"-that is, the emergence of resistance from a previously susceptible isolate. The appropriate control group for this question is patients who previously had a susceptible organism isolated.
Literature review. Studies were rated "yes" under "control group selected from study base" in table 2 if control patients were assembled from the source or base population of interest relative to the aims of each study. Among the 37 studies reviewed, 24 (65%) chose a control group which consisted of patients with positive clinical cultures for the susceptible organism; 13 chose a control group representative of the base population of interest. In 10 of 13 studies that relied on a control group representative of the base population, surveillance cultures were done to identify case patients. None of the other 24 studies used surveillance cultures to identify case patients. Therefore, when case patients are defined on the basis of nonsurveillance cultures or clinician-driven cultures, the predominant study design is to use patients with the susceptible organism as control patients.
The following data highlight how improper selection of control group potentially leads to antibiotics incorrectly being identified as causal risk factors. Among the 24 studies that used patients colonized or infected with the susceptible form of the organism as the control group, 15 used a multivariate analysis to assess antibiotics as individual risk factors. Thirteen (87%) of these identified an antibiotic or an antibiotic class as a risk factor that may be a risk factor for the resistant organisms but may also be identified as a risk factor solely because it may be protective against becoming part of the control group.
For example, 3 studies identified treatment with vancomycin as a risk factor for the development of VRE with the control group being patients infected with the susceptible organism. Although the comparison between patients with vancomycinsusceptible enterococci (VSE) and those with VRE is convenient and appears logical, patients with VSE do not represent the base population. Vancomycin therapy may be identified as a risk factor not because it is a risk factor for development of VRE but because very few to no patients in the VSE control group received vancomycin; the receipt of vancomycin may prevent patients from entering into the VSE control group. The importance of control group selection on the identification of risk factors for development of VRE has been demonstrated in a meta-analysis [10] that aimed to assess whether vancomycin therapy was a risk factor for development of VRE. The metaanalysis demonstrated that studies that used a control group of patients with VSE identified vancomycin therapy as a risk factor (pooled OR, 10.7), whereas studies that used a second control group (no patients with VRE and not limited to patients with VSE, therefore similar to all admissions) revealed a far weaker association (OR, 2.7). This weaker risk was then eliminated when studies were controlled for time at risk prior to the outcome.
Another study in our systematic review identified imipenem therapy as a risk factor for development of imipenem-resistant P. aeruginosa. Treatment with imipenem may have been identified as a risk factor for development of imipenem-resistant P. aeruginosa not because it is a true risk factor but because receiving imipenem may prevent patients from being in the control group of patients with cultures of imipenem-susceptible P. aeruginosa. The magnitude of decreased frequency of exposure to active antibiotics in susceptible-organism control patients depends on a number of factors, which includes inoculum size of infection and the timing of the antibiotic administration relative to cultures. Recommendation 1. A control group derived from an appropriate sampling method of the base population is preferred in studies of antibiotic-resistant pathogens that seek to identify factors causally related to antibiotic resistance. Measures such as the risk ratio or rate ratio are not meaningfully inferred from studies that rely on control patients that consist of patients with the susceptible form of the organism. The effect of antibiotics may be distorted by use of control patients with the susceptible form of the organism.
Principle 2: adjustment for time at risk. Wacholder et al. [4] comment that an important principle of case-control studies is the deconfounding principle that: "confounding should not be allowed to distort the estimation of effect." An important confounding variable for nosocomial case-control studies that analyze antibiotic resistance is the time at risk. We define the time at risk as the duration of time between admission and detection of the antibiotic-resistant organism on culture. For studies that use patients with the antibiotic-susceptible organism as controls, the time at risk is the number of days between admission and detection of the susceptible organism on culture. For control patients derived from a sampling of all hospitalized patients or patients in long-term care facilities, the time at risk is the number of days between admission and discharge.
We regard this time at risk as a particularly important confounding variable because it represents the duration of the atrisk period both for exposure to antibiotics and for acquisition of the antibiotic-resistant organism: patients who are admitted to the hospital for longer periods are likely to receive a greater number of antibiotics and are also more likely to become colonized or infected with an antibiotic-resistant organism. In addition, time at risk is likely correlated with the severity of illness of patients, which is another important confounding variable.
Literature review. Studies were rated "yes" under "adjustment for time at risk" in table 2 if they analyzed or adjusted for time at risk in their statistical analyses. Among the 37 studies, the measurement of the duration of time at risk was not applicable in 4 studies. Of the remaining 33, only 11 (33%) assessed the duration of time at risk. Two additional studies analyzed total length of stay. However, total length of stay combines both the duration of time at risk and the duration from acquisition of resistance to discharge. The latter period is a result of the outcome of interest and should not be included in the period of time at risk. Recommendation 2. Time at risk is an important confounding variable in studies that assess treatment with antibiotics as risk factors for development of antibiotic-resistant organisms. The period of time at risk needs to be measured and controlled in a stratified or multivariate analysis or by study design (matching). The period of time at risk should not include a duration of time that occurs after the outcome of interest has occurred.
Principle 3: adjustment for comorbid illnesses. An important confounding variable among studies that analyze antibiotic resistance is comorbid illnesses. Comorbid illnesses, such as immunocompromised states, are likely causal components for the outcome of antibiotic resistance. Comorbid illnesses are confounding variables: patients with comorbid conditions are more likely both to have acquired an antibioticresistant pathogen and to have received an antibiotic that is the risk factor of interest. Comorbid illnesses likely increase the risk of acquisition of antibiotic-resistant organisms [11] [12] [13] . To have an unbiased estimate of the association between antibiotic use and antibiotic resistance, there is a need to assess and statistically control for comorbid illnesses in the study design or by means of statistical analysis.
Literature review. Studies were rated "yes" under "adjustment for severity of illness" in table 2 if they analyzed or adjusted for comorbid illness in their statistical analyses. Of the 37 studies, the measurement of the severity of illness was not applicable in 2. Of the remaining 35, 27 (77%) assessed comorbid conditions. Nine (26%) used previously described severity of illness predictors or scores: 2 used the Charlson score [14] , 5 used the McCabe and Jackson scale [15] , and 2 used an APACHE score [16] .
Recommendation 3. Comorbid illnesses are an important potential confounding variable in studies which assess antibiotics as risk factors for antibiotic-resistant organisms. Comorbid illnesses need to be measured and controlled in a stratified or multivariate analysis or by study design (matching).
Having a standardized score that could be used in multiple different studies to control for comorbid illnesses would be ideal. This is likely why studies have used the Charlson, APACHE, and McCabe and Jackson scores, which are standardized scores that were initially developed for non-infectious disease outcomes. It is important to make a distinction between the use of a score to adjust for confounding and its use as a predictor. It is worth noting that severity of illness predictors, such as the APACHE score [16] , the Charlson score [14] , and the McCabe and Jackson scale [15] , have not been formally assessed either in their ability to control for confounding due to comorbid illnesses in studies of antibiotic resistance or in their ability to predict colonization or infection with antibioticresistant organisms. A review by the Centers for Disease Control and Prevention in 1996 demonstrated that the existing severity of illness scoring systems did not fare well in the prediction of nosocomial infection rates in patients in intensive care units [17] . These existing severity of illness scores need to be epidemiologically and statistically assessed in the area of antibioticresistant organisms.
CONCLUSION
In this study, we attempt to address methodological principles that are important in case-control studies that analyze individual risk factors for antibiotic-resistant organisms. A systematic review of studies that analyzed risk factors for antibiotic-resistant pathogens was conducted, with a focus on methods for control group selection and adjustment of confounding factors. The principles outlined in this review do not encompass all of the methodological issues relevant to studies of resistant pathogens. Our recommendations may help provide explanations for past and future contradictions among studies identifying antibiotics as risk factors for resistant organisms.
We hope that this study leads to more attention and awareness of the principles of epidemiological study design as applied to clinical investigations of antibiotic resistance. Our desire is that, when future studies are performed that are more firmly grounded in epidemiological principles, "true" causal risk factors will be identified and thus will lead to appropriate targets for interventions aimed at curbing the increasing emergence of antibiotic resistance.
